Provided by Tiger Trade Technology Pte. Ltd.

Fractyl Health

0.6590
-0.0828-11.16%
Pre-market: 0.69640.0374+5.68%07:25 EDT
Volume:2.38M
Turnover:1.64M
Market Cap:104.55M
PE:-0.59
High:0.7590
Open:0.7406
Low:0.6450
Close:0.7418
52wk High:2.45
52wk Low:0.3772
Shares:158.65M
Float Shares:128.00M
Volume Ratio:1.45
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1193
EPS(LYR):-1.8600
ROE:-778.33%
ROA:-74.57%
PB:-62.79
PE(LYR):-0.35

Loading ...

Fractyl Health Q1 EPS $0.06 Beats $(0.16) Estimate

Benzinga Earnings
·
May 13

Fractyl Health Q1 FY26 turns to net income of $9.22 million; operating loss narrows 15.9% to $20.82 million

Reuters
·
May 13

Fractyl Health Inc - Reiterates Cash Runway Guidance Into Early 2027

THOMSON REUTERS
·
May 13

Fractyl Health Inc: Q1 EPS $0.06

THOMSON REUTERS
·
May 13

Press Release: Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates

Dow Jones
·
May 13

Fractyl Health wins Dutch clearance to start RJVA-001 first-in-human trial

Reuters
·
May 11

Fractyl Health Inc - Plans Rjva-001 Study in Australia; Regulatory Feedback Expected Q3 2026

THOMSON REUTERS
·
May 11

Fractyl Health Authorized to Initiate First-in-Human Trial of Rjva-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

THOMSON REUTERS
·
May 11

Fractyl Health Inc - First Patient Dosing and Preliminary Data for Rjva-001 Expected in H2 2026

THOMSON REUTERS
·
May 11

Fractyl Health Inc - Rejuva Clinical Development Funded Into Early 2027 With No Change to Capital Plans

THOMSON REUTERS
·
May 11

Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes

GlobeNewswire
·
May 11

Fractyl Health Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
May 09

Fractyl Health updates financial calendar ahead of quarterly results webcast

Reuters
·
May 05

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

GlobeNewswire
·
May 05

Reiterated Buy on Strong Risk‑Reward Ahead of REMAIN‑1 Pivotal Data; $8 Price Target Unchanged

TIPRANKS
·
Apr 29

Fractyl Health announces annual shareholder meeting

Reuters
·
Apr 25

Fractyl Health Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 24

Health Rounds: Procedure to treat type 2 diabetes helps keep off weight after patients stop GLP-1 drugs

Reuters
·
Apr 24

Fractyl Health Earnings Call: Revita Nears Key Pivotal Test

TIPRANKS
·
Mar 28

Fractyl Health Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 26